THX Pharma Appoints Sophie Jacq Lapointe to Accelerate International Commercialization
The biopharmaceutical company has announced the appointment of an industry executive to its Board of Directors, who has contributed to over twenty product launches at Roche, Sanofi, Sanofi Genzyme, and Ipsen. This appointment is part of THX Pharma's new strategy aimed at accelerating the registration and international commercialization of its candidates.
Sophie Jacq Lapointe brings to THX Pharma extensive experience in the pharmaceutical and biotechnological sectors. She has held leadership and strategic roles at Roche, Sanofi, Sanofi Genzyme, and Ipsen. Among her commercial successes is the launch of Dupixent at Sanofi Genzyme, described as one of the most successful in the group in Europe. She has also contributed to over twenty product launches in France, Europe, and emerging markets.
A Reinforcement Aligned with the Company's New Trajectory
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The appointment of Sophie Jacq Lapointe aligns with the strategic context of THX Pharma, which is now focused on accelerating the registration, market access, and international commercialization of its medical candidates for rare diseases. Her expertise in corporate strategy, portfolio development, and market access is expected to enhance the company's ability to progress in these areas. Mathieu Charvériat, CEO of THX Pharma, emphasizes that her commercialization experience is 'particularly in tune with the new trajectory' of the company. The appointment also follows the departure of Rodolphe Besserve from the Board of Directors.
Related
SectorIndustrie Pharmaceutique et Biotechnologie›Biotechnologie
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 2025
Key reported figures
Revenue: 813K€
Net income: -3 002 k€
Guidance from the release
L'accord stratégique récemment conclu avec Biocodex,...
THX Pharma renforce sa solidité financière.
Risks mentioned
Pression sur les coûts de développement liée aux essais cliniques.
Incertitude réglementaire sur les projets de commercialisation.
Opportunities identified
Lancement clinique de TX01 et Batten-1 en 2026.
Accord stratégique avec Biocodex.
Visibilité financière sécurisée avec Biocodex.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
